Below are the most recent publications written about "Peptides, Cyclic" by people in Profiles.
-
Nuckols VR, Shoemaker LN, Kuczmarski AV, Haigh KM, McGinty SJ, Del Vecchio AR, Schwab AI, Edwards DG, Taylor HS, Wenner MM. Short-term estradiol administration does not restore endothelin-B receptor-mediated vasodilation in postmenopausal women. Am J Physiol Heart Circ Physiol. 2025 Feb 01; 328(2):H327-H332.
-
Bashir B, Wang JS, Falchook G, Fontana E, Arkenau HT, Carter L, Galot R, Basu B, Greystoke A, Subbiah V, Richardson DL, Orr H, Bennett G, Sharma R, Xu H, Paganoni P, Xu C, Campbell C, McKean M. Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. J Clin Oncol. 2024 Oct 10; 42(29):3443-3452.
-
Randolph CE, Dwyer MB, Aumiller JL, Dixon AJ, Inoue A, Osei-Owusu P, Wedegaertner PB. Enhanced membrane binding of oncogenic G protein aqQ209L confers resistance to inhibitor YM-254890. J Biol Chem. 2022 11; 298(11):102538.
-
Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022 07; 18(7):691-701.
-
Lee Ching C, Kenyon L, Berk M, Park C. Rheumatoid meningitis sine arthritis. J Neuroimmunol. 2019 03 15; 328:73-75.
-
Mo H, Hedskog C, Lawitz E, Brainard DM, Yang J, Delaney W, Worth A, Miller MD. Antiviral response and resistance analysis of treatment-na?ve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res. 2017 04; 140:151-157.
-
Yang H, Yang C, Wang Y, Rhodes G, Robinson M, Cheng G, Qi X, Mo H, Tian Y, Pakdaman R, Sheng XC, Kim CU, Delaney WE. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256. Antivir Ther. 2017; 22(5):413-420.
-
Beier JI, Guo L, Ritzenthaler JD, Joshi-Barve S, Roman J, Arteel GE. ?Fibrin-mediated integrin signaling plays a critical role in hepatic regeneration after partial hepatectomy in mice. Ann Hepatol. 2016 Sep-Oct; 15(5):762-72.
-
Traczewski MM, Deane J, Sahm D, Brown SD, Chesnel L. Impact of Variations in Test Method Parameters on In Vitro Activity of Surotomycin against Clostridium difficile and Surotomycin Quality Control Limits for Broth Microdilution and Agar Dilution Susceptibility Testing. J Clin Microbiol. 2016 Mar; 54(3):749-53.
-
Kirino Y, Hama M, Takase-Minegishi K, Kunishita Y, Kishimoto D, Yoshimi R, Asami Y, Ihata A, Oba MS, Tsunoda S, Ohno S, Ueda A, Takeno M, Ishigatsubo Y. Predicting joint destruction in rheumatoid arthritis with power Doppler, anti-citrullinated peptide antibody, and joint swelling. Mod Rheumatol. 2015; 25(6):842-8.